← Eichor
Condition: High Risk Plasma Cell Neoplasms Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: High Risk Plasma Cell Neoplasms

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

High Dose Ascorbic Acid (HDAA) in Patients With Plasma Cell Disorders
Phase 1 · 1 location(s) · University of Arkansas · NCT06313502Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
Phase 1/Phase 2 · 39 location(s) · CellCentric Ltd. · NCT04068597Expression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients
Phase 2/Phase 3 · 6 location(s) · University Hopsital Schleswig Holstein Campus Lübeck · NCT05665140Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma
Phase 2 · 1 location(s) · University of Rochester · NCT05597345Study of SGR-1505 in Mature B-Cell Neoplasms
Phase 1 · 36 location(s) · Schrödinger, Inc. · NCT05544019Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma
Phase 1/Phase 2 · 1 location(s) · Shenzhen Geno-Immune Medical Institute · NCT06429150Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma
Phase 2 · 1 location(s) · Emory University · NCT05208307Discontinuation Study
NA · 1 location(s) · University College Cork · NCT05866757A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Parti
Phase 1/Phase 2 · 32 location(s) · Regeneron Pharmaceuticals · NCT05828511Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
Phase 3 · 747 location(s) · ECOG-ACRIN Cancer Research Group · NCT03937635Ciltacabtagene Autoleucel in High-Risk Smoldering Multiple Myeloma
Phase 2 · 1 location(s) · PETHEMA Foundation · NCT06574126Personalized NK Cell Therapy in CBT
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT02727803Comparation of Chidamide Plus VRD (Bortezomib, Lenalidomide, Dexamethasone) With VRD Regimen for Primary High-Risk Multi
Phase 1/Phase 2 · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT04025450Use of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma
Phase 2 · 25 location(s) · Stichting European Myeloma Network · NCT06183489Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection
Phase 4 · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT06409702A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies
Phase 1/Phase 2 · 11 location(s) · IDP Discovery Pharma S.L. · NCT05908409A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
Phase 3 · 2 location(s) · Regeneron Pharmaceuticals · NCT07393282Immuno-PRISM (PRecision Intervention Smoldering Myeloma)
Phase 2 · 3 location(s) · Irene Ghobrial, MD · NCT05469893Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple Myeloma
Phase 4 · 1 location(s) · Second Affiliated Hospital, School of Medicine, Zhejiang Uni · NCT05722405Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Mu
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT06207799ASCT in Combination With C-CAR088 for Treating Patients With Ultra High-risk Multiple Myeloma (MM)
Phase 1/Phase 2 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT05632380Prevention of Delayed CINV After Autologous Transplant: Olanzapine-Containing Regimen vs. Dexamethasone-Containing Regim
Phase 3 · 1 location(s) · The Affiliated People's Hospital of Ningbo University · NCT07413809Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE)
Phase N/A · 1 location(s) · Dana-Farber Cancer Institute · NCT03689595Isatuximab and Iberdomide as Immunotherapy for High Risk in Smouldering Myeloma
Phase 2 · 2 location(s) · University College, London · NCT06762769Predicting Progression of Developing Myeloma in a High-Risk Screened Population and General Population
Phase N/A · 3 location(s) · Tel-Aviv Sourasky Medical Center · NCT05837884BCMA CAR-T for Dynamic High-risk Multiple Myeloma
Phase 2 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT06880393Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multipl
Phase 2 · 1 location(s) · Emory University · NCT04776395A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment o
Phase 1 · 1 location(s) · M.D. Anderson Cancer Center · NCT05055063High-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT)
Phase N/A · 1 location(s) · Yigeng Cao,MD,PhD · NCT07205523Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Essen Biotech · NCT07410494
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.